A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Phase 3
680
about 2.8 years
18+
37 sites in AL, AR, CA +13
What this study is about
This trial is testing whether ziltivekimab, a new medication, can be used to treat participants with heart failure and inflammation. Participants will either receive ziltivekimab or a placebo (an inactive substance). The treatment they receive is determined by chance.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Ziltivekimab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Primary: Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)
Secondary: Change in N-terminal-pro-brain natriuretic peptide (NT-proBNP), Change in eGFR (CKD-EPI), Change in high-sensitivity C-reactive protein (hs-CRP), Change in six-minute walk distance (6MWD), Change in subscales of KCCQ (total symptom score, physical limitations score, social limitations score, and health-related quality of life), Participant achieving threshold for clinically meaningful within-participant change in 6-minute walk distance (6MWD) (yes/no), Participant achieving threshold for clinically meaningful within-participant change in KCCQ CSS (yes/no), Participants improving 10 points or more in KCCQ-CSS (yes/no)
Cardiology / Heart